Top Stories
FDA approves Imcivree for acquired hypothalamic obesity on March 19, offsetting EMANATE Phase 3 miss in rare MC4R pathway obesities
The FDA approved Imcivree (setmelanotide) on March 19, 2026, one day ahead of its March 20 PDUFA date, as a treatment for acquired hypothalamic obesity in adults and pediatric patients aged 4 years and older, according to Rhythm Pharmaceuticals. The approval is based on the Phase 3 TRANSCEND trial, which demonstrated an 18.4% placebo-adjusted BMI reduction in 142 patients. Rhythm estimates approximately 10,000 people in the United States live with acquired hypothalamic obesity. Goldman Sachs has estimated peak sales for the AHO indication at approximately $2 billion, making it the most commercially significant indication in the Imcivree franchise. The approval arrives days after the company reported that its Phase 3 EMANATE basket trial failed to achieve statistical significance in any of four rare genetic obesity populations linked to the MC4R pathway, according to BioSpace. The 52-week EMANATE study enrolled nearly 300 patients across substudies in heterozygous POMC/PCSK1 (4.3% placebo-adjusted BMI reduction), LEPR (3.6%), SRC1/NCOA1 (4.0%), and SH2B1 (1.7%) variant carriers. Analysts at Stifel, who had previously modeled approximately $300 million in risk-adjusted sales across those four indications by 2034, called the outcome disappointing, as reported by Clinical Trials Arena. Rhythm intends to continue analyzing the EMANATE dataset and evaluate development paths with its next-generation MC4R agonists bivamelagon and RM-718. Imcivree now holds approvals for acquired hypothalamic obesity, POMC/PCSK1 and LEPR deficiency (biallelic), and Bardet-Biedl syndrome.
Lynavoy wins FDA approval as first therapy for cholestatic pruritus in primary biliary cholangitis, days after Alfasigma closes $690M licensing deal with GSK
The FDA approved Lynavoy (linerixibat), an ileal bile acid transporter inhibitor, as the first therapy specifically indicated for cholestatic pruritus in adult patients with primary biliary cholangitis, a rare autoimmune liver disease affecting an estimated 100,000 to 130,000 people in the United States according to nationwide prevalence studies, according to Fierce Pharma. The approval came days ahead of the March 24 PDUFA date and is based on the Phase 3 GLISTEN trial showing significant, rapid, and sustained improvements in itch symptoms and sleep disturbance versus placebo over 24 weeks. GSK, which developed linerixibat, had licensed worldwide rights to Alfasigma for up to $690 million on March 9, including a $300 million upfront payment and $100 million triggered by this approval. Alfasigma considers itself positioned for commercialization given its hepatology portfolio, which formerly included Intercept Pharmaceuticals Ocaliva before its voluntary market withdrawal last year. Pharmaphorum reported that analysts project Lynavoy peak sales of approximately $500 million annually. The drug enters a PBC market alongside Ipsen Iqirvo and Gilead Livdelzi, with Mirum Pharmaceuticals rival IBAT inhibitor volixibat also in late-stage development. Lynavoy has orphan drug designation in the US, EU, and Japan.
Taysha advances TSHA-102 Rett syndrome pivotal trial dosing on track for Q2 2026 completion as FDA clears younger patient cohort expansion
Taysha Gene Therapies dosed multiple Rett syndrome patients in the REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites and dosing on track for completion in the second quarter of 2026, according to the company. The company also received FDA clearance to initiate the ASPIRE trial in patients aged 2 and older, expanding the addressable population and providing earlier intervention data critical for pediatric gene therapy positioning. Rett syndrome affects approximately 6,000 to 9,000 diagnosed individuals in the United States, according to the National Organization for Rare Disorders, with MECP2 gene mutations driving progressive neurological decline. TSHA-102 uses an AAV9 vector for CNS-directed MECP2 transgene delivery. The REVEAL trial design includes functional outcome measures such as Clinical Global Impression and Rett Syndrome Behaviour Questionnaire, with durability assessments extending through 5 years post-dosing. Successful completion of dosing by mid-2026 positions the company for potential pivotal data readout in 2027, though CNS transgene expression variability and immunogenicity management remain key technical uncertainties across the field.
Pipeline Watch
Sarepta Therapeutics intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval, per company regulatory update. The submissions follow FDA feedback and will incorporate confirmatory efficacy data from ongoing studies in Duchenne muscular dystrophy patients amenable to exon 45 and exon 53 skipping. Traditional approval conversion would eliminate accelerated approval withdrawal risk and strengthen commercial positioning.
Sarepta began screening and enrollment in ENDEAVOR Cohort 8, which will evaluate approximately 25 non-ambulatory Duchenne muscular dystrophy participants receiving sirolimus as part of an enhanced immunosuppressive regimen with ELEVIDYS gene therapy, according to company announcement. The regimen aims to mitigate immunogenicity risk and optimize transgene expression in older, non-ambulatory patients who represent a distinct biology relative to younger ambulatory cohorts.
Edward Wild, professor of Neurology at UCL Huntington Disease Centre, described the AMT-130 gene therapy program as having reached a turning point at the Advanced Therapies 2026 conference in London, according to Pharmaceutical Technology. The AAV5-based gene therapy demonstrated 75% slower disease progression at 3 years in high-dose patients versus external controls. However, the FDA has indicated that Phase I/II data are insufficient for a marketing application and recommended a prospective, randomized, sham-controlled study. UniQure plans a Type B meeting in Q2 2026. Wild drew parallels with early HIV treatments, noting that while the field has a foot in the door, surgical delivery bottlenecks and regulatory alignment remain critical challenges. Huntington disease affects an estimated 30,000 people in the United States and tens of thousands more across Europe and the United Kingdom, according to a 2022 systematic review and meta-analysis reporting prevalence of 8.87 per 100,000 in North America and 6.37 per 100,000 in Europe.
AstraZeneca announced plans to build a commercial cell therapy manufacturing and supply base plus an innovation center in Shanghai, positioning it as the first multinational pharma with end-to-end cell therapy capabilities in China, as reported by BioPharma Dive. The facility will manufacture and supply CAR-T therapies for China and other Asian markets, including the BCMA/CD19 dual-target candidate acquired through its 2023 buyout of Gracell Biotechnologies. The investment is part of a broader $15 billion commitment to China through 2030 covering cell therapy and radioconjugate capabilities across drug discovery, clinical development, and manufacturing.
Just 47% of EMA-approved cell and gene therapy product indications are accessible to patients in the Netherlands, placing it among the lowest-access EU countries alongside Belgium, Norway, and Ireland, according to Pharmaceutical Technology. Speaking at the Advanced Therapies Congress in London, Gilead Director of Market Access Peter Fassler noted that high-cost drugs placed in the Dutch reimbursement lock take nearly two years on average to become available. Pharmacoeconomic challenges are frequently driven by single-arm trial designs common to rare disease programs, highlighting the tension between gene therapy evidence generation and European reimbursement standards.
A speech-in-noise perception study sponsored by Cincinnati Children's Hospital Medical Center is now recruiting patients with Fragile X syndrome, per ClinicalTrials.gov. The trial investigates auditory processing differences which may inform intervention strategies and outcome measure development for future therapeutic trials. Fragile X syndrome affects approximately 1 in 4,000 males and 1 in 8,000 females according to the CDC, and represents the most common inherited form of intellectual disability, with no approved disease-modifying therapies.
Competitive Landscape
Sarepta planned April 2026 supplemental NDA submissions for AMONDYS 45 and VYONDYS 53 traditional approval conversion, combined with ENDEAVOR Cohort 8 sirolimus evaluation for ELEVIDYS in non-ambulatory patients, positions the company to expand its Duchenne portfolio across mutation types and disease stages.
| Product | Modality | Status | Target Population |
|---|---|---|---|
| ELEVIDYS | Gene Therapy | Approved | Ambulatory DMD |
| AMONDYS 45 | Exon Skipping | Accelerated Approval | Exon 45 Amenable |
| VYONDYS 53 | Exon Skipping | Accelerated Approval | Exon 53 Amenable |
| ENDEAVOR Cohort 8 | Gene Therapy + Sirolimus | Phase 3 | Non-Ambulatory DMD |
Lynavoy approval gives PBC patients a third active treatment option with a differentiated IBAT inhibitor mechanism, following the voluntary withdrawal of Ocaliva and 2024 launches of Ipsen Iqirvo (dual PPAR agonist) and Gilead Livdelzi (PPAR-delta activator). Mirum Pharmaceuticals rival IBAT inhibitor volixibat remains in late-stage testing, potentially creating a within-class competitive dynamic.
| Drug | Company | Mechanism | Status |
|---|---|---|---|
| Lynavoy | Alfasigma/GSK | IBAT Inhibitor | FDA Approved (Mar 2026) |
| Iqirvo | Ipsen/Genfit | Dual PPAR Agonist | Approved (2024) |
| Livdelzi | Gilead | PPAR-delta Activator | Approved (2024) |
| Volixibat | Mirum | IBAT Inhibitor | Phase 3 |
The FDA request for a prospective randomized sham-controlled study of AMT-130, despite 75% disease-slowing signal from Phase I/II data with external controls, underscores the persistent gap between rare disease trial feasibility and regulatory evidence standards. The outcome may influence how other CNS gene therapy developers including Taysha (Rett syndrome) and Passage Bio design their pivotal programs, particularly for surgically delivered AAV therapies where sham controls raise ethical complexity.
Forward Looking
- Rhythm Pharmaceuticals secured FDA approval for Imcivree in acquired hypothalamic obesity on March 19, 2026, one day ahead of its PDUFA date — Rhythm's commercial launch execution, payer coverage strategy, and physician adoption in the estimated 10,000-patient AHO population will determine whether the product reaches Goldman Sachs' approximately $2 billion peak sales estimate.
- Taysha completion of TSHA-102 REVEAL trial dosing in Q2 2026 positions the company for potential 2027 pivotal data readout in Rett syndrome, a high unmet need pediatric indication with no approved disease-modifying therapies.
- Sarepta April 2026 supplemental NDA submissions for AMONDYS 45 and VYONDYS 53 traditional approval conversion will test FDA acceptance of confirmatory efficacy data packages for exon-skipping therapies initially granted accelerated approval.
- UniQure Type B meeting with FDA expected Q2 2026 to explore next steps for AMT-130 Huntington disease gene therapy after the agency recommended a prospective randomized sham-controlled study despite positive Phase I/II external-control data.
- Alfasigma commercialization strategy for Lynavoy in PBC pruritus will test whether a mid-sized specialty pharma can compete effectively against Ipsen and Gilead in a rare liver disease market now populated by three approved therapies.